NOTCH3 Limits the Epithelial-mesenchymal Transition and Predicts a Favorable Clinical Outcome in Esophageal Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2021 May 27

PMID 34042293

Citations 9

Authors

Norihiro Matsuura

Koji Tanaka

Makoto Yamasaki

Kotaro Yamashita

Takuro Saito

Tomoki Makino

Kazuyoshi Yamamoto

Tsuyoshi Takahashi

Yukinori Kurokawa

Kiyokazu Nakajima

Hidetoshi Eguchi

Hiroshi Nakagawa

Yuichiro Doki

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is the deadliest of all human squamous cell carcinomas and is characterized by chemotherapy resistance and poor prognosis associated with the epithelial-mesenchymal transition (EMT). A subset of ESCC displays loss-of-function mutations in genes encoding Notch receptor family members, including NOTCH3. Although Notch signaling regulates EMT in ESCC cells, the role of NOTCH3 in EMT and chemotherapy resistance remains elusive. This study aimed to examine the role of NOTCH3 in EMT and chemotherapy resistance, and determine whether NOTCH3 expression can be used to predict the response to chemotherapy.

Methods: In vitro and in vivo assays were conducted to clarify the contribution of NOTCH3 to chemotherapy resistance. Using specimens from 120 ESCC patients treated with neoadjuvant chemotherapy, we compared the expression levels of NOTCH3 and genes involved in EMT according to the degree of chemotherapy sensitivity.

Results: In ESCC cells, chemotherapy resistance was associated with NOTCH3 downregulation and concurrent activation of EMT. RNA interference to silence NOTCH3 resulted in induction of the EMT marker Vimentin (VIM), leading to chemotherapy resistance in ESCC cells. Conversely, ectopic expression of the activated form of NOTCH3 suppressed EMT and sensitized cells to chemotherapy. Results of chromatin immunoprecipitation assays suggested that NOTCH3 may repress transcription of the VIM.

Conclusions: Our findings suggest that NOTCH3 may control chemotherapy sensitivity by regulating EMT. NOTCH3 may serve as a novel biomarker to predict better clinical outcomes in ESCC patients.

Citing Articles

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies.

Montagner A, Arleo A, Suzzi F, DAssoro A, Piscaglia F, Gramantieri L Biomolecules. 2025; 14(12.

PMID: 39766289 PMC: 11674819. DOI: 10.3390/biom14121581.

D-loop mutations in mitochondrial DNA are a risk factor for chemotherapy resistance in esophageal cancer.

Harino T, Tanaka K, Motooka D, Masuike Y, Takahashi T, Yamashita K Sci Rep. 2024; 14(1):31653.

PMID: 39738117 PMC: 11685473. DOI: 10.1038/s41598-024-80226-3.

Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.

Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S Signal Transduct Target Ther. 2024; 9(1):128.

PMID: 38797752 PMC: 11128457. DOI: 10.1038/s41392-024-01828-x.

Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial-Mesenchymal Transition.

Davis J, Mitra Ghosh T, Mazumder S, Mitra A, Bird R, Arnold R Int J Mol Sci. 2023; 24(10).

PMID: 37239838 PMC: 10218056. DOI: 10.3390/ijms24108490.

The expression of ASAP3 and NOTCH3 and the clinicopathological characteristics of adult glioma patients.

Su L, Ji M, Liu L, Sang W, Xue J, Wang B Open Med (Wars). 2022; 17(1):1724-1741.

PMID: 36382054 PMC: 9623729. DOI: 10.1515/med-2022-0585.

References

Lin H, Liang Y, Dou X, Chen C, Wei X, Zeng D . Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018; 7(8):59. PMC: 6087713. DOI: 10.1038/s41389-018-0069-z. View

Li Q, Hutchins A, Chen Y, Li S, Shan Y, Liao B . A sequential EMT-MET mechanism drives the differentiation of human embryonic stem cells towards hepatocytes. Nat Commun. 2017; 8:15166. PMC: 5418622. DOI: 10.1038/ncomms15166. View

Natsuizaka M, Whelan K, Kagawa S, Tanaka K, Giroux V, Chandramouleeswaran P . Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nat Commun. 2017; 8(1):1758. PMC: 5700926. DOI: 10.1038/s41467-017-01500-9. View

Okamoto K, Ninomiya I, Hirose A, Kinoshita J, Nakamura K, Oyama K . [Therapeutic Strategies with Multidisciplinary Local Therapy for Postoperative Recurrence of Esophageal Cancer]. Gan To Kagaku Ryoho. 2017; 43(12):1490-1492. View

Whelan K, Chandramouleeswaran P, Tanaka K, Natsuizaka M, Guha M, Srinivasan S . Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance. Oncogene. 2017; 36(34):4843-4858. PMC: 5570661. DOI: 10.1038/onc.2017.102. View

Kagawa S, Natsuizaka M, Whelan K, Facompre N, Naganuma S, Ohashi S . Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene. 2014; 34(18):2347-59. PMC: 4268095. DOI: 10.1038/onc.2014.169. View

Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi J, Nevo J, Gjerdrum C . Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2010; 30(12):1436-48. DOI: 10.1038/onc.2010.509. View

Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S . Identification of the tumour transition states occurring during EMT. Nature. 2018; 556(7702):463-468. DOI: 10.1038/s41586-018-0040-3. View

Nieto M, Huang R, Jackson R, Thiery J . EMT: 2016. Cell. 2016; 166(1):21-45. DOI: 10.1016/j.cell.2016.06.028. View

10.

Xu T, Park S, Giaimo B, Hall D, Ferrante F, Ho D . RBPJ/CBF1 interacts with L3MBTL3/MBT1 to promote repression of Notch signaling via histone demethylase KDM1A/LSD1. EMBO J. 2017; 36(21):3232-3249. PMC: 5666606. DOI: 10.15252/embj.201796525. View

11.

Rodriguez M, Peralta-Leal A, OValle F, Rodriguez-Vargas J, Gonzalez-Flores A, Majuelos-Melguizo J . PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013; 9(6):e1003531. PMC: 3681683. DOI: 10.1371/journal.pgen.1003531. View

12.

Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K . Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2016; 28(1):116-120. DOI: 10.1093/annonc/mdw439. View

13.

. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus. 2017; 14(1):1-36. PMC: 5222932. DOI: 10.1007/s10388-016-0551-7. View

14.

Machuca-Parra A, Bigger-Allen A, Sanchez A, Boutabla A, Cardona-Velez J, Amarnani D . Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL. J Exp Med. 2017; 214(8):2271-2282. PMC: 5551569. DOI: 10.1084/jem.20161715. View

15.

Basu D, Nguyen T, Montone K, Zhang G, Wang L, Diehl J . Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene. 2010; 29(29):4170-82. PMC: 3039880. DOI: 10.1038/onc.2010.170. View

16.

Castel D, Mourikis P, Bartels S, Brinkman A, Tajbakhsh S, Stunnenberg H . Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 2013; 27(9):1059-71. PMC: 3656323. DOI: 10.1101/gad.211912.112. View

17.

Hayashi Y, Ohnuma K, Furue M . Pluripotent Stem Cell Heterogeneity. Adv Exp Med Biol. 2019; 1123:71-94. DOI: 10.1007/978-3-030-11096-3_6. View

18.

Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman R, Nakagawa M, Wu L . NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology. 2010; 139(6):2113-23. PMC: 2997138. DOI: 10.1053/j.gastro.2010.08.040. View

19.

Qian X, Tang S, Shen Y, Chen L, Cheng X, Wan X . Notch1 Affects Chemo-resistance Through Regulating Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian cancer cells. Int J Med Sci. 2020; 17(9):1215-1223. PMC: 7294924. DOI: 10.7150/ijms.44683. View

20.

Sawada G, Niida A, Uchi R, Hirata H, Shimamura T, Suzuki Y . Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. Gastroenterology. 2016; 150(5):1171-1182. DOI: 10.1053/j.gastro.2016.01.035. View